Related Experiment Video
Updated: Jan 22, 2026

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies
Published on: November 7, 2015
Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy
Isabel Heidegger1, Andreas Pircher2, Renate Pichler1
1Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
Abstract:
Renal cell cancer (RCC) is a highly vascularized and immunogenic tumor type. The inhibition of vessel formation by anti-angiogenic therapies, as well as the stimulation of the immune system by immunotherapy has revolutionized the therapeutic landscape of RCC in recent years. Nevertheless, both therapies are associated with therapy resistance due to a highly dynamic, adaptive and heterogeneous tumor microenvironment (TME). The aim of this short review article is to provide an overview of the components of the RCC TME as well as to discuss their contribution to disease progression. In addition, we report on preclinical and clinical findings and how the different TME components can be modulated to impede treatment progression as well as to overcome therapy resistance to anti-angiogenic or immunomodulating therapy concepts. Furthermore, we discuss the predictive and prognostic role of the TME in RCC therapy. We also report on the concept of combinational targeting of anti-angiogenic therapies and immune checkpoint inhibitor therapy, also including the latest results of clinical studies discussed at recent oncological meetings. Finally, promising new therapeutic targets within the TME are mentioned.
Insights
Renal cell cancer (RCC) treatments face resistance from the tumor microenvironment (TME). Understanding and targeting TME components can improve anti-angiogenic and immunotherapy effectiveness in RCC.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Renal cell cancer (RCC) is a vascularized and immunogenic malignancy.
- Anti-angiogenic and immunotherapies have transformed RCC treatment.
- Therapy resistance is a significant challenge, often driven by the tumor microenvironment (TME).
Purpose of the Study:
- To review the components of the RCC TME.
- To discuss the TME's role in disease progression and treatment resistance.
- To explore strategies for modulating the TME to enhance therapeutic outcomes.
Main Methods:
- Literature review of preclinical and clinical findings.
- Analysis of TME components and their impact on therapy.
- Discussion of combined therapeutic strategies and novel targets.
Main Results:
- The RCC TME is dynamic, adaptive, and heterogeneous, contributing to resistance.
- Modulating TME components offers potential to overcome resistance to anti-angiogenic and immunotherapies.
- Combinational targeting, including anti-angiogenic agents and immune checkpoint inhibitors, shows promise.
Conclusions:
- The TME plays a critical role in RCC progression and treatment response.
- Targeting the TME is essential for overcoming resistance and improving patient outcomes.
- Further research into novel TME-targeting strategies is warranted.
More Related Videos
10:33Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
Published on: April 29, 2014
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Tumor Microenvironment
Continuous Renal Replacement Therapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy